




Instance: composition-en-94c552a1c89feea3465242a8fa5ba0ae
InstanceOf: CompositionUvEpi
Title: "Composition for neoclarityn Package Leaflet"
Description:  "Composition for neoclarityn Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/00/161/001-013"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp94c552a1c89feea3465242a8fa5ba0ae)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - neoclarityn"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Neoclarityn is and what it is used for </li>
<li>What you need to know before you take Neoclarityn </li>
<li>How to take Neoclarityn </li>
<li>Possible side effects </li>
<li>How to store Neoclarityn </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What neoclarityn is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What neoclarityn is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Neoclarityn is 
Neoclarityn contains desloratadine which is an antihistamine. </p>
<p>How Neoclarityn works 
Neoclarityn is an antiallergy medicine that does not make you drowsy. It helps control your allergic 
reaction and its symptoms. </p>
<p>When Neoclarityn should be used 
Neoclarityn relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages 
caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 
12 years of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and 
itchy, red or watery eyes.  </p>
<p>Neoclarityn is also used to relieve the symptoms associated with urticaria (a skin condition caused by 
an allergy). These symptoms include itching and hives. </p>
<p>Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and 
sleep. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take neoclarityn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take neoclarityn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Neoclarityn 
- if you are allergic to desloratadine, or any of the other ingredients of this medicine (listed in 
section 6) or to loratadine. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before taking Neoclarityn:</p>
<ul>
<li>if you have poor kidney function. </li>
<li>if you have medical or familial history of seizures. </li>
</ul>
<p>Children and adolescents 
Do not give this medicine to children less than 12 years of age. </p>
<p>Other medicines and Neoclarityn 
There are no known interactions of Neoclarityn with other medicines.<br />
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.  </p>
<p>Neoclarityn with food, drink and alcohol<br />
Neoclarityn may be taken with or without a meal.<br />
Use caution when taking Neoclarityn with alcohol.  </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor, or pharmacist for advice before taking this medicine. 
Taking Neoclarityn is not recommended if you are pregnant or nursing a baby. 
There is no data available on male/female fertility. </p>
<p>Driving and using machines 
At the recommended dose, this medicine is not expected to affect your ability to drive or use 
machines. Although most people do not experience drowsiness, it is recommended not to engage in 
activities requiring mental alertness, such as driving a car or operating machinery until you have 
established your own response to the medicine.  </p>
<p>Neoclarityn tablet contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take neoclarityn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take neoclarityn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>Use in adults and adolescents 12 years of age and over 
The recommended dose is one tablet once a day with water, with or without food.  </p>
<p>This medicine is for oral use.<br />
Swallow the tablet whole.  </p>
<p>Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are 
suffering from and will determine for how long you should take Neoclarityn. 
If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less 
than 4 weeks), your physician will recommend you a treatment schedule that will depend on the 
evaluation of the history of your disease. 
If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more 
than 4 weeks), your physician may recommend you a longer term treatment. </p>
<p>For urticaria, the duration of treatment may be variable from patient to patient and therefore you 
should follow the instructions of your physician. </p>
<p>If you take more Neoclarityn than you should 
Take Neoclarityn only as it is prescribed for you. No serious problems are expected with accidental 
overdose. However, if you take more Neoclarityn than you were told to, tell your doctor, pharmacist or 
nurse immediately. </p>
<p>If you forget to take Neoclarityn 
If you forget to take your dose on time, take it as soon as possible and then go back to your regular 
dosing schedule. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Neoclarityn 
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>During the marketing of Neoclarityn, cases of severe allergic reactions (difficulty in breathing, wheezing, 
itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, 
stop taking the medicine and seek urgent medical advice straight away. </p>
<p>In clinical studies in adults, side effects were about the same as with a dummy tablet. However, 
fatigue, dry mouth and headache were reported more often than with a dummy tablet. In adolescents, 
headache was the most commonly reported side effect. </p>
<p>In clinical studies with Neoclarityn, the following side effects were reported as: </p>
<p>Common: the following may affect up to 1 in 10 people 
* fatigue<br />
<em> dry mouth<br />
</em> headache  </p>
<p>During the marketing of Neoclarityn, the following side effects were reported as: </p>
<p>Very rare: the following may affect up to 1 in 10,000 people 
* severe allergic reactions<br />
<em> rash<br />
</em> pounding or irregular heartbeat<br />
<em> fast heartbeat<br />
</em> stomach ache<br />
<em> feeling sick (nausea)<br />
</em> vomiting<br />
<em> upset stomach<br />
</em> diarrhoea<br />
<em> dizziness<br />
</em> drowsiness<br />
<em> inability to sleep<br />
</em> muscle pain<br />
<em> hallucinations<br />
</em> seizures<br />
<em> restlessness with increased body movement<br />
</em> liver inflammation<br />
* abnormal liver function tests  </p>
<p>Not known: frequency cannot be estimated from the available data 
* unusual weakness<br />
<em> yellowing of the skin and/or eyes<br />
</em> increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for 
instance to UV lights of a solarium<br />
* changes in the way the heart beats  </p>
<ul>
<li>abnormal behaviour  </li>
<li>aggression  </li>
<li>weight increased, increased appetite  </li>
<li>depressed mood </li>
<li>dry eyes </li>
</ul>
<p>Children 
Not known: frequency cannot be estimated from the available data 
* slow heartbeat<br />
<em> change in the way the heart beats<br />
</em> abnormal behaviour 
* aggression </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store neoclarityn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store neoclarityn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.  </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month.  </p>
<p>Do not store above 30 C. Store in the original package.  </p>
<p>Do not use this medicine if you notice any change in the appearance of the tablets. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Neoclarityn contains 
* The active substance is desloratadine 5 mg 
* The other ingredients of the tablet are calcium hydrogen phosphate dihydrate, microcrystalline 
cellulose, maize starch, talc. Tablet coating contains film coat (containing lactose monohydrate 
(see section 2  Neoclarityn tablet contains lactose ), hypromellose, titanium dioxide, 
macrogol 400, indigotin (E132)), clear coat (containing hypromellose, macrogol 400), carnauba 
wax, white wax. </p>
<p>What Neoclarityn looks like and contents of the pack 
Neoclarityn 5 mg film-coated tablet is light blue, round and embossed with elongated letters  S  and 
 P  on one side and plain on the other. 
Neoclarityn 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 
30, 50 or 100 tablets. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Marketing Authorisation Holder: 
N.V. Organon 
Kloosterstraat 6 
5349 AB Oss 
The Netherlands </p>
<p>Manufacturer: Organon Heist bv, Industriepark 30, 2220 Heist-op-den-Berg, Belgium. </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovyb<br />
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>( . .)  . . -   <br />
 .: +359 2 806 3dpoc.bulgaria@organon.com </p>
<p>Luxembourg/Luxemburg 
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>esk  republika 
Organon Czech Republic s.r.o. 
Tel.: +420 233 010 dpoc.czech@organon.com </p>
<p>Magyarorsz g 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com </p>
<p>Danmark 
Organon Denmark ApS 
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel.: 00800 66550123 (+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>N.V. Organon 
 : +30-216 6008 sterreich 
Organon Austria GmbH 
Tel: +43 (0) 1 263 28 dpoc.austria@organon.com </p>
<p>Espa a 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com 
Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France 
T l: +33 (0) 1 57 77 32 Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>Rom nia 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com </p>
<p>Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podru nica 
Ljubljana 
Tel: +386 1 300 10 dpoc.slovenia@organon.com </p>
<p>sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovakia@organon.com  </p>
<p>Italia 
Organon Italia S.r.l. 
Tel: +39 06 90259dpoc.italy@organon.com </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Organon Pharma B.V., Cyprus branch 
 : +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
 rvalsts komersanta  Organon Pharma B.V.<br />
p rst vniec ba 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited 
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com </p>
<p>This leaflet was last revised in &lt;{MM/YYYY}&gt;&lt;{month YYYY}&gt; </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website 
http://www.ema.europa.eu. </p>
<p>Package leaflet: Information for the patient  </p>
<p>Neoclarityn 0.5 mg/ml oral solution<br />
desloratadine </p>
<p>Read all of this leaflet carefully before you start taking this medicine because it contains 
important information for you. 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor, pharmacist or nurse. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 
even if their signs of illness are the same as yours. 
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible 
side effects not listed in this leaflet. See section 4.</p>         </div>"""      



Instance: composition-da-94c552a1c89feea3465242a8fa5ba0ae
InstanceOf: CompositionUvEpi
Title: "Composition for neoclarityn Package Leaflet"
Description:  "Composition for neoclarityn Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/00/161/001-013"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp94c552a1c89feea3465242a8fa5ba0ae)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - neoclarityn"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Neoclarityn 
3. Sådan skal du tage Neoclarityn 
4. Bivirkninger<br />
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What neoclarityn is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What neoclarityn is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Neoclarityn er 
Neoclarityn indeholder desloratadin, som er et antihistamin. </p>
<p>Sådan virker Neoclarityn 
Neoclarityn er et lægemiddel mod allergi, som ikke gør dig døsig. Det hjælper med at regulere din 
allergiske reaktion og dens symptomer. </p>
<p>Hvornår Neoclarityn skal bruges 
Neoclarityn lindrer symptomer forbundet med allergisk snue (irritation af vævet i de nasale passager 
forårsaget af allergi, for eksempel høfeber eller støvmideallergi) hos voksne og unge i alderen 12 år og 
derover. Symptomerne indbefatter nysen, løbende eller kløende næse, kløe i ganen og kløende, røde 
eller løbende øjne. </p>
<p>Neoclarityn anvendes også til at lindre symptomerne i forbindelse med nældefeber (en hudlidelse 
forårsaget af allergi). Symptomerne indbefatter kløe og kløende udslæt. </p>
<p>Lindring af disse symptomer varer en hel dag og hjælper dig til at genoptage dine normale daglige 
aktiviteter og søvn. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take neoclarityn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take neoclarityn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Neoclarityn 
- hvis du er allergisk over for desloratadin eller et af de øvrige indholdsstoffer i Neoclarityn 
(angivet i punkt 6) eller over for loratadin. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Neoclarityn. 
- hvis du har dårlig nyrefunktion.<br />
- hvis du tidligere har haft krampeanfald eller nogen i familien har haft det. </p>
<p>Børn og unge 
Giv ikke dette lægemiddel til børn under 12 år. </p>
<p>Brug af anden medicin sammen med Neoclarityn 
Der er ingen kendte interaktioner mellem Neoclarityn og andre lægemidler. 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. </p>
<p>Brug af Neoclarityn sammen med mad, drikke og alkohol 
Neoclarityn kan tages med eller uden mad. 
Du skal udvise forsigtighed, hvis du tager Neoclarityn sammen med alkohol. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel.<br />
Det frarådes, at du tager Neoclarityn, hvis du er gravid, eller hvis du ammer dit spædbarn. 
Der er ingen information tilgængelig om virkningen på frugtbarheden hos mænd og kvinder. </p>
<p>Trafik- og arbejdssikkerhed 
Ved den anbefalede dosis forventes dette lægemiddel ikke at påvirke evnen til at køre bil og betjene 
maskiner. Selvom de fleste mennesker ikke oplever døsighed, frarådes det at beskæftige sig med 
aktiviteter, der kræver mental årvågenhed, for eksempel køre bil og betjene maskiner, indtil din 
reaktion på dette lægemiddel er fastlagt. </p>
<p>Neoclarityn-tabletter indeholder lactose 
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take neoclarityn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take neoclarityn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Brug til voksne og unge i alderen 12 år og derover<br />
Den anbefalede dosis er en tablet en gang dagligt sammen med vand, med eller uden mad. </p>
<p>Dette lægemiddel skal tages gennem munden. 
Tabletten skal sluges hel. </p>
<p>Med hensyn til varigheden af behandlingen, vil din læge bestemme hvilken type allergisk snue, du 
lider af, og vil fastsætte, hvor længe du skal tage Neoclarityn. 
Hvis din allergiske snue er forbigående (tilstedeværelse af symptomer i mindre end 4 dage per uge 
eller i mindre end 4 uger), vil din læge anbefale dig en behandlingsplan, som vil afhænge af 
vurderingen af din sygdomshistorie. 
Hvis din allergiske snue er vedvarende (tilstedeværelse af symptomer i 4 dage eller mere per uge og i 
mere end 4 uger), vil din læge måske anbefale dig en længerevarende behandling. </p>
<p>For nældefeber kan varigheden af behandling variere fra patient til patient, og du skal derfor følge din 
læges instruktioner. </p>
<p>Hvis du har taget for meget Neoclarityn 
Tag udelukkende Neoclarityn således, som det er ordineret til dig. Ved fejlagtig overdosis forventes 
ingen alvorlige problemer. Men kontakt straks lægen, apotekspersonalet eller sygeplejersken, hvis du 
tager flere Neoclarityn-tabletter, end du har fået besked på. </p>
<p>Hvis du har glemt at tage Neoclarityn 
Hvis du glemmer at tage din medicin til tiden, så tag den snarest muligt og vend derefter tilbage til din 
sædvanlige medicineringsplan. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Neoclarityn 
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Under markedsføring af Neoclarityn er tilfælde af alvorlige allergiske reaktioner 
(vejrtrækningsbesvær, hiven efter vejret, kløe, kløende udslæt og hævelse) blevet rapporteret meget 
sjældent. Stop med at tage medicinen og søg straks akut lægehjælp, hvis du får nogle af disse alvorlige 
bivirkninger. </p>
<p>I kliniske studier med voksne var bivirkningerne nogenlunde de samme som ved en placebotablet. 
Træthed, mundtørhed og hovedpine blev imidlertid rapporteret hyppigere end ved en placebotablet. 
Hovedpine var den hyppigst rapporterede bivirkning hos unge. </p>
<p>I kliniske studier med Neoclarityn er følgende bivirkninger blevet rapporteret som: </p>
<p>Almindelige: følgende kan forekomme hos op til 1 ud af 10 personer </p>
<ul>
<li>
<p>træthed </p>
</li>
<li>
<p>mundtørhed </p>
</li>
<li>
<p>hovedpine </p>
</li>
</ul>
<p>Efter markedsføring af Neoclarityn er følgende bivirkninger blevet rapporteret: </p>
<p>Meget sjældne: følgende kan forekomme hos op til 1 ud af 10.000 personer </p>
<ul>
<li>
<p>alvorlige allergiske reaktioner </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>hjertebanken eller uregelmæssig hjerterytme </p>
</li>
<li>
<p>hurtig hjerterytme (puls) </p>
</li>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>mavebesvær </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>døsighed </p>
</li>
<li>
<p>søvnbesvær </p>
</li>
<li>
<p>muskelsmerter </p>
</li>
<li>
<p>hallucinationer </p>
</li>
<li>
<p>krampeanfald </p>
</li>
<li>
<p>rastløshed med øget kropsbevægelse </p>
</li>
<li>
<p>leverbetændelse </p>
</li>
<li>
<p>unormale prøver for leverfunktion </p>
</li>
</ul>
<p>Ikke kendt: hyppigheden kan ikke vurderes ud fra tilgængelige data </p>
<ul>
<li>
<p>usædvanlig mathedsfølelse </p>
</li>
<li>
<p>huden og/eller øjnene får en gullig farve </p>
</li>
<li>
<p>øget hudfølsomhed over for sollys, selv i overskyet vejr, og over for ultraviolet (UV) lys, f.eks. 
UV-lys i et solarium </p>
</li>
<li>
<p>ændringer i måden hjertet slår </p>
</li>
<li>
<p>unormal adfærd </p>
</li>
<li>
<p>aggression </p>
</li>
<li>
<p>vægtforøgelse, øget appetit </p>
</li>
<li>
<p>nedtrykt sindstilstand </p>
</li>
<li>
<p>øjentørhed </p>
</li>
</ul>
<p>Børn og unge 
Ikke kendt: hyppigheden kan ikke vurderes ud fra tilgængelige data </p>
<ul>
<li>
<p>langsomme hjerteslag </p>
</li>
<li>
<p>ændring i måden hjertet slår </p>
</li>
<li>
<p>unormal adfærd </p>
</li>
<li>
<p>aggression </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store neoclarityn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store neoclarityn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og blisteren efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. Opbevares i den originale yderpakning. </p>
<p>Tag ikke lægemidlet, hvis du bemærker ændringer i tabletternes udseende. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Neoclarityn indeholder:</p>
<ul>
<li>Aktivt stof: desloratadin 5 mg </li>
<li>Øvrige indholdsstoffer i tabletten: calciumhydrogenphosphatdihydrat, mikrokrystallinsk 
cellulose, majsstivelse og talkum. Tabletovertrækket består af filmovertræk (indeholdende 
lactosemonohydrat (se punkt 2 “Neoclarityn-tabletter indeholder lactose"), hypromellose, 
titandioxid, macrogol 400, indigotin (E132)), klart lag (indeholdende hypromellose, 
macrogol 400), carnaubavoks og hvid bivoks. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Neoclarityn 5 mg filmovertrukne tabletter er lyseblå, runde og præget med forlængede bogstaver “S" 
og “P" på en side og klar på den anden. 
Neoclarityn 5 mg filmovertrukne tabletter er pakket i enkeltdosisblisterpakninger med 1, 2, 3, 5, 7, 10, 
14, 15, 20, 21, 30, 50 eller 100 tabletter. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Indehaver af markedsføringstilladelsen: 
N.V. Organon 
Kloosterstraat 6 
5349 AB Oss 
Holland </p>
<p>Fremstiller: Organon Heist bv, Industriepark 30, 2220 Heist-op-den-Berg, Belgien. </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovybė 
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>България 
Органон (И.А.) Б.В. - клон България 
Тел.: +359 2 806 3dpoc.bulgaria@organon.com </p>
<p>Luxembourg/Luxemburg 
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Česká republika 
Organon Czech Republic s.r.o. 
Tel.: +420 233 010 dpoc.czech@organon.com </p>
<p>Magyarország 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com </p>
<p>Danmark 
Organon Denmark ApS 
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel.: 00800 66550(+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>Ελλάδα 
N.V. Organon 
Τηλ: +30-216 6008 
Österreich 
Organon Austria GmbH 
Tel: +43 (0) 1 263 28 dpoc.austria@organon.com </p>
<p>España 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com 
Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France 
Tél: +33 (0) 1 57 77 32<br />
Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>România 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com </p>
<p>Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podružnica Ljubljana 
Tel: +386 1 300 10 info.slovenia@organon.com </p>
<p>Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovenia@organon.com </p>
<p>Italia 
Organon Italia S.r.l. 
Tel: +39 06 90259dpoc.italy@organon.com </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Κύπρος 
Organon Pharma B.V., Cyprus branch 
Τηλ: +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
Ārvalsts komersanta “Organon Pharma B.V." 
pārstāvniecība 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited 
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com </p>
<p>Denne indlægsseddel blev senest ændret &lt;{MM/YYYY}&gt;&lt;{måned ÅÅÅÅ}&gt; </p>
<p>Du kan finde yderligere oplysninger om Neoclarityn på Det Europæiske Lægemiddelagenturs 
http://www.ema.europa.eu. 
 Indlægsseddel: Information til patienten </p>
<p>Neoclarityn 0,5 mg/ml oral opløsning 
desloratadin </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er mere, du vil vide. 
- Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give medicinen 
til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har.<br />
- Kontakt lægen, apotekspersonalet eller sygeplejersken, hvis du får bivirkninger, herunder 
bivirkninger, som ikke er nævnt i denne indlægsseddel. Se punkt 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-94c552a1c89feea3465242a8fa5ba0ae
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for neoclarityn Package Leaflet for language en"
Description: "ePI document Bundle for neoclarityn Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-94c552a1c89feea3465242a8fa5ba0ae"
* entry[0].resource = composition-en-94c552a1c89feea3465242a8fa5ba0ae

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp94c552a1c89feea3465242a8fa5ba0ae"
* entry[=].resource = mp94c552a1c89feea3465242a8fa5ba0ae
                            
                    
Instance: bundlepackageleaflet-da-94c552a1c89feea3465242a8fa5ba0ae
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for neoclarityn Package Leaflet for language da"
Description: "ePI document Bundle for neoclarityn Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-94c552a1c89feea3465242a8fa5ba0ae"
* entry[0].resource = composition-da-94c552a1c89feea3465242a8fa5ba0ae

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp94c552a1c89feea3465242a8fa5ba0ae"
* entry[=].resource = mp94c552a1c89feea3465242a8fa5ba0ae
                            
                    



Instance: mp94c552a1c89feea3465242a8fa5ba0ae
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Neoclarityn 5 mg film-coated tablets"
Description: "Neoclarityn 5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/00/161/001-013"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Neoclarityn 5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 94c552a1c89feea3465242a8fa5ba0aeListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "neoclarityn"

* status = #current
* mode = #working

* title = "List of all ePIs associated with neoclarityn"

* subject = Reference(mp94c552a1c89feea3465242a8fa5ba0ae)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#neoclarityn "neoclarityn"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-94c552a1c89feea3465242a8fa5ba0ae) // neoclarityn en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-94c552a1c89feea3465242a8fa5ba0ae) // neoclarityn da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-94c552a1c89feea3465242a8fa5ba0ae
InstanceOf: List

* insert 94c552a1c89feea3465242a8fa5ba0aeListRuleset
    